Global healthcare strategist and operator joins to accelerate HealthTech commercialisation to the United States
Oxford, UK – 10 September 2025 – Oxford Science Enterprises (OSE) has appointed Benny Axt as an Entrepreneur-in-Residence (EIR) within its HealthTech team, bringing over 15 years’ global experience building and scaling healthcare ventures around the world.
Benny was previously Vice President of Strategy at Dialogue Health Technologies Inc., where he supported US market entrance and helped grow the company from venture-backed startup to IPO and acquisition by Sun Life. He has also held leadership roles at DaVita, a Fortune 500 healthcare provider, and has advised multiple early-stage digital health startups as a board member and consultant. His leadership spans operations, corporate development, human resources, and global expansion. He recently won a health care innovation accelerator at Dartmouth College and was recognised with a Pitch Award for work on a novel neuromodulation device targeting chronic cancer pain. He holds a Master of Health Care Delivery Science from Dartmouth College, an MBA from Thunderbird School of Global Management, and a BA from the University of Wisconsin–Madison.
As an Entrepreneur-in-Residence, Benny will work with OSE’s HealthTech team and Oxford’s academic community to identify and ultimately found a new high-impact venture. As OSE's first US Entrepreneur-In-Residence, Benny’s arrival marks the start of an initiative to bring seasoned American healthcare executives into the Oxford innovation ecosystem, enabling acceleration of commercial entry into one of the world’s largest healthcare markets.
Katherine Ward, Operating Partner, HealthTech at OSE, said:
"We’re thrilled to welcome Benny to the HealthTech team. His deep experience across global healthcare – spanning companies at different stages and markets – makes him ideally suited to founding and leading a new venture. Benny’s appointment builds on the success of our EIR model in HealthTech, which has already led to the creation of pioneering companies such as Neu Health, co-founded by former EIR Caroline Cake. In this role, he will source cutting-edge science from Oxford to tackle real-world healthcare challenges and build a company capable of delivering life-changing outcomes at scale.”
Benny Axt, Entrepreneur-in-Residence at OSE, commented:
"Joining OSE is a once-in-a-career opportunity. It’s a privilege to join such a dynamic ecosystem committed to turning science into high-impact ventures, and I’m eager to work with entrepreneurs, investors, and Oxford’s academic leaders to bring new healthtech companies to life – translating scientific excellence from the University of Oxford into global healthcare impact.”
OSE attracts experienced founders and proven leaders to Oxford through its Entrepreneurs-in-Residence programme, partnering with them to identify breakthrough ideas and ultimately found new ventures. The programme provides direct access to Oxford’s world-class science, capital, and a clear path to spinout. It is a core part of OSE’s mission to find, fund and build world-changing companies, and has already led to the creation of pioneering spinouts including Neu Health, Amber Therapeutics, and Salience Labs.
OSE’s HealthTech team is on a mission to build the next big transformation in healthcare – making it more intelligent, personalised and accessible. The team focuses on breakthrough innovations in care delivery, diagnostics & devices, and data & discovery – from AI-powered platforms and next-generation diagnostics to novel medical devices and digital health tools. Together, these ventures are reimagining care, accelerating research, and advancing global health.
Oxford Science Enterprises (OSE) is an independent, billion-pound investment company that finds, funds and builds transformational science and technology companies emerging from Oxford’s world-leading research. Our portfolio of companies is focused across three high-impact sectors – Deep Tech, Life Sciences, and HealthTech – with the ambition of tackling some of the world’s greatest challenges. To date, OSE has collaborated with over 300 international investors, collectively investing over £3 billion in more than 100 groundbreaking companies.